Published in N Engl J Med on May 03, 2007
HORIZON-PFT: Pivotal Fracture Trial | NCT00049829
Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS) (ZABAS) | NCT04742010
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Osteoporosis: now and the future. Lancet (2011) 5.81
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (2013) 5.57
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ (2015) 4.29
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med (2015) 2.92
Low-energy distal radius fractures in middle-aged and elderly men and women--the burden of osteoporosis and fracture risk : A study of 1794 consecutive patients. Osteoporos Int (2009) 2.77
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab (2010) 2.29
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med (2014) 2.20
Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res (2012) 2.05
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
Cardiovascular effects of calcium supplementation. Osteoporos Int (2011) 1.96
Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med (2008) 1.85
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun (2015) 1.63
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int (2013) 1.60
Risks and benefits of bisphosphonates. Br J Cancer (2008) 1.57
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (2008) 1.54
Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int (2009) 1.53
Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res (2014) 1.52
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
Digital X-ray radiogrammetry of hand or wrist radiographs can predict hip fracture risk--a study in 5,420 women and 2,837 men. Eur Radiol (2012) 1.49
Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol (2010) 1.48
The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol (2010) 1.44
The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol (2013) 1.44
The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol (2012) 1.43
New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol (2011) 1.43
Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int (2008) 1.42
UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos (2017) 1.40
Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc (2009) 1.39
Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study. BMC Musculoskelet Disord (2011) 1.37
Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int (2009) 1.37
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol (2008) 1.36
Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006. Osteoporos Int (2009) 1.33
Increasing options for the treatment of osteoporosis. N Engl J Med (2009) 1.32
Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther (2013) 1.29
Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med (2007) 1.29
The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int (2014) 1.27
Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res (2010) 1.25
Prevalent vertebral fractures in black women and white women. J Bone Miner Res (2008) 1.25
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis (2012) 1.22
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab (2014) 1.20
FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int (2009) 1.19
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc (2010) 1.16
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg (2008) 1.15
Individualizing osteoporosis therapy. Osteoporos Int (2012) 1.15
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int (2009) 1.14
Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2010) 1.12
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol (2008) 1.12
Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ (2009) 1.12
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States. Osteoporos Int (2008) 1.11
Drug-induced uveitis. J Ophthalmic Inflamm Infect (2013) 1.11
Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2013) 1.10
Treatments for osteoporosis - looking beyond the HORIZON. N Engl J Med (2007) 1.10
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat (2009) 1.09
Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis. Osteoporos Int (2010) 1.07
Identify fracture-critical regions inside the proximal femur using statistical parametric mapping. Bone (2008) 1.07
Treatment of osteoporosis in men. Bone (2012) 1.06
Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc (2010) 1.06
Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int (2008) 1.06
The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int (2012) 1.05
Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 1.04
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer (2011) 1.04
Death, debility, and destitution following hip fracture. J Gerontol A Biol Sci Med Sci (2013) 1.03
Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther (2009) 1.03
Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis (2012) 1.02
Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One (2009) 1.01
Gender differences in osteoporosis and fractures. Clin Orthop Relat Res (2011) 1.00
Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int (2008) 0.99
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskelet Disord (2011) 0.99
Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int (2007) 0.99
Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab (2014) 0.99
Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol (N Y) (2010) 0.99
Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab (2009) 0.99
Current and future treatment options in osteoporosis. Eur J Clin Pharmacol (2011) 0.98
A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res (2014) 0.98
A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int (2011) 0.98
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res (2008) 0.98
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging (2012) 0.98
Effect of zoledronate on oral wound healing in rats. Clin Cancer Res (2010) 0.98
Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol (2015) 0.98
Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord (2009) 0.98
Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int (2009) 0.97
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int (2010) 0.97
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med (2014) 11.30
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (2010) 10.85
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60
Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med (2006) 7.45
A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med (2010) 6.13
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38
In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab (2005) 5.31
Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ (2008) 5.14
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 4.63
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med (2011) 4.28
Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med (2010) 4.24
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 4.01
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Randomized controlled trial of patching vs acupuncture for anisometropic amblyopia in children aged 7 to 12 years. Arch Ophthalmol (2010) 3.92
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab (2008) 3.67
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40
Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med (2005) 3.39
A comparison of prediction models for fractures in older women: is more better? Arch Intern Med (2009) 3.37
Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women. J Bone Miner Res (2008) 3.33
Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause (2004) 3.33
Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res (2007) 3.31
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Duration of lactation and risk factors for maternal cardiovascular disease. Obstet Gynecol (2009) 3.18
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci (2007) 3.16
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 3.14
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10
A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc (2009) 3.09
Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab (2007) 3.05
Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med (2011) 2.98
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell (2009) 2.79
Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement. J Clin Endocrinol Metab (2012) 2.78
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74